Novel camptothecin derivatives as topoisomerase I inhibitors

Bibliography

• Wall ME, Wani MC, Cook CE, et al. Plan antitumor agents. I. The isolation and structure of Camptothecin, a novel alkaloid leukemia and tumor inhibitor form Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90
   Web of Science ®Google Scholar
• Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970;54(6):461
   PubMedGoogle Scholar
• Creaven PJ, Allen LM. Renal clearance of camptothecin (NSC-100880): effect of urine volume. Cancer Chemother Rep 1973;57(2):175-84
   PubMedGoogle Scholar
• Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260(27):14873-8
   PubMed Web of Science ®Google Scholar
• Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34(1):98-107
   PubMed Web of Science ®Google Scholar
• Sawada S, Okajima S, Aiyama R, et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull (Tokyo) 1991;39(6):1446-50
   PubMed Web of Science ®Google Scholar
• Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10- [4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47(22):5944-7
   PubMed Web of Science ®Google Scholar
• Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51(16):4187-91
   PubMed Web of Science ®Google Scholar
• Ahn SK, Choi NS, Jeong BS, et al. Practical synthesis of (S)-7-(2-isopropylamino)ethylcamptothecin hydrocloride, potent topoisomerase I inhibitor. J Heterocycl Chem 2000;37(5):1141-4
   Web of Science ®Google Scholar
• Chong Kun Dang Corp. (Korea). A process of manufacturing camptothecin derivatives. WO9902530; 1999
   Google Scholar
• Wani MC, Nicholas AW, Wall ME. Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5′(RS)-1,5-dioxo-5′-ethyl-5′-hydroxy-2′H,5′H,6′H-6′-oxopyrano[3′ ,4′- f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. J Med Chem 1987;30(12):2317-9
   PubMedGoogle Scholar
• Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32(3):715-20
   PubMed Web of Science ®Google Scholar
• Wani MC, Nicholas AW, Wall ME. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. J Med Chem 1986;29(11):2358-63
   PubMed Web of Science ®Google Scholar
• Adams DJ, Dewhirst MW, Flowers JL, et al. Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemother Pharmacol 2000;46(4):263-71
   Google Scholar
• Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 1997;57(10):1934-8
   PubMed Web of Science ®Google Scholar
• Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000;922:188-94
   PubMed Web of Science ®Google Scholar
• Yang CH, Schneider E, Kuo ML, et al. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000;60(6):831-7
   Google Scholar
• Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006;13(27):3291-305
   PubMed Web of Science ®Google Scholar
• Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995;1262(1):1-14
   PubMed Web of Science ®Google Scholar
• Stivers JT, Harris TK, Mildvan AS. Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation. BioChem 1997;36(17):5212-22
   PubMed Web of Science ®Google Scholar
• Champoux JJ. Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3′-terminus of the nicked DNA. J Mol Biol 1978;118(3):441-6
   PubMedGoogle Scholar
• Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48(7):1722-6
   PubMed Web of Science ®Google Scholar
• Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6(10):789-802
   PubMed Web of Science ®Google Scholar
• Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 1993;53(24):5908-14
   PubMed Web of Science ®Google Scholar
• Tsao YP, D'Arpa P, Liu LF. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/ cyclin B. Cancer Res 1992;52(7):1823-9
   PubMed Web of Science ®Google Scholar
• Kharbanda S, Rubin E, Gunji H, et al. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 1991;51(24):6636-42
   PubMed Web of Science ®Google Scholar
• Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Ann Rev Pharmacol Toxicol 2001;41:53-77
   PubMed Web of Science ®Google Scholar
• Mao Y, Sun M, Desai SD, Liu LF. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci USA 2000;97(8):4046-51
   PubMed Web of Science ®Google Scholar
• Desai SD, Li TK, Rodriguez-Bauman A, et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001;61(15):5926-32
   PubMed Web of Science ®Google Scholar
• Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75(6):1262-71
   PubMed Web of Science ®Google Scholar
• Beretta GL, Perego P, Zunino F. Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets 2008;12(10):1243-56
   PubMed Web of Science ®Google Scholar
• Staker BL, Hjerrild K, Feese MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002;99(24):15387-92
   PubMed Web of Science ®Google Scholar
• Ioanoviciu A, Antony S, Pommier Y, et al. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 2005;48(15):4803-14
   PubMedGoogle Scholar
• Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48(7):2336-45
   PubMed Web of Science ®Google Scholar
• Basf AG. Production of camptothecin and camptothecin-like compounds. US389029; 1975
   Google Scholar
• Shionogi & Co. Camptothecin analogues. US4031098; 1977
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. 7-Substituted camptothecin derivatives and process for their preparation. EP56692; 1982
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. 7-Substituted camptothecin derivatives and process for their preparation. US4399276; 1983;
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Camptothecin derivatives. US4399282; 1983
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Camptothecin derivatives, processes for preparing same, formulations containing such derivatives and their use. EP74256; 1983
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Camptothecin derivatives and processes for preparing same. US4473692; 1984
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Photochemical process for preparing camptothecin derivatives. US4545880; 1985
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Camptothecin-1-oxide derivatives, process for preparing same, formulations comprising said derivatives and said derivatives for use in producing an antitumor effect. EP74770; 1983
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Camptothecin-1-oxide derivatives. US4513138; 1985
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. New camptothecin derivatives and process for their preparation. EP88642; 1983
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. New camptothecin derivatives and process for preparing same. EP137145; 1985
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. New camptothecin derivatives and process for preparing same. US4604463; 1986
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Hexa-cyclic compound. EP296597; 1988
   Google Scholar
• Daiichi Pharmaceutical Co, Ltd; Kabushiki Kaisha Yakult Honsha. Hexa-cyclic camptothecin derivatives. US4939255; 1990
   Google Scholar
• Daiichi Pharmaceutical Co, Ltd; Kabushiki Kaisha Yakult Honsha. Hexa-cyclic compound. US5061795; 1991
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. New camptothecin derivatives and process for preparing same. EP325247; 1989
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Camptothecin derivatives. US5061800; 1991
   Google Scholar
• SmithKline Beckman Corporation. Water soluble camptothecin analogs. EP321122; 1989
   Google Scholar
• SmithKline Beckman Corporation. Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells. US5004758; 1991
   Google Scholar
• Research Triangle Institute. Synthesis of camptothecin and analogs thereof. US4894456; 1990
   Google Scholar
• Research Triangle Institute. Camptothecin analogs as potent inhibitors of human colorectal cancer. WO9105556; 1991
   Google Scholar
• Raymond E, Campone M, Stupp R, et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 2002;38(10):1348-50
   PubMed Web of Science ®Google Scholar
• Schoffski P, Herr A, Vermorken JB, et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002;38(6):807-13
   PubMed Web of Science ®Google Scholar
• Giovanella BC, Stehlin JS, Hinz HR, et al. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Int J Oncol 2002;20(1):81-8
   PubMed Web of Science ®Google Scholar
• Yakult Honsha. Novel 9-camptothecin and its preparation. JP59051288; 1984
   Google Scholar
• Liew ST, Yang LX. Design, synthesis and development of novel camptothecin drugs. Curr Pharm Des 2008;14(11):1078-97
   PubMed Web of Science ®Google Scholar
• Research Triangle Institute. 10,11-Methylenedioxy-20 (RS) camptothecin and 10, 11-Methylenedioxy-20 (S) – camptothecin analog. EP418099; 1990
   Google Scholar
• Cummings J, Ethell BT, Jardine L, et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 2003;63(23):8443-50
   PubMed Web of Science ®Google Scholar
• Glaxo, Inc. Water soluble camptothecin derivatives. EP540099; 1993
   Google Scholar
• Glaxo, Inc. Preparation of water soluble camptothecin derivatives. US5342947; 1994
   Google Scholar
• Glaxo Wellcome, Inc. Water soluble camptothecin derivatives. US5559235; 1996
   Google Scholar
• Luzzio MJ, Besterman JM, Emerson DL, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 1995;38(3):395-401
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Kunka R, DeMaria D, et al. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. Br J Cancer 1998;78(10):1329-36
   Google Scholar
• Stevenson JP, DeMaria D, Sludden J, et al. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Ann Oncol 1999;10(3):339-44
   PubMed Web of Science ®Google Scholar
• Gamucci T, Paridaens R, Heinrich B, et al. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol 2000;11(7):793-7
   PubMed Web of Science ®Google Scholar
• Gelmon K, Hirte H, Fisher B, et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs 2004;22(3):263-75
   PubMed Web of Science ®Google Scholar
• Giles FJ, Tallman MS, Garcia-Manero G, et al. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 2004;100(7):1449-58
   PubMed Web of Science ®Google Scholar
• Glaxo, Inc. Water soluble camptothecin derivatives. WO9411377; 1994
   Google Scholar
• Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives, their production and use as antitumor agents. EP556585; 1993
   Google Scholar
• Kyorin Pharmaceutical Co, Ltd. Fluoroethylcamptothecin derivatives. EP471358; 1992
   Google Scholar
• Daiichi Pharmaceutical Co, Ltd; Kabushiki Kaisha Yakult Honsha. Hexa-cyclic compound. EP296597; 1988
   Google Scholar
• Kabushiki Kaisha Yakult Honsha. Hexa-cyclic compounds. EP495432; 1992
   Google Scholar
• Daiichi Pharmaceutical Co, Ltd; Kabushiki Kaisha Yakult Honsha. Hexa-cyclic compound. US5637770; 1997
   Google Scholar
• Daiichi Pharmaceutical Co, Ltd; Kabushiki Kaisha Yakult Honsha. Substituted 1H,12H-benz-[de]pyrano[3´,4´:6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione compound. US5658920; 1997
   Google Scholar
• Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995;86(8):776-82
   PubMedGoogle Scholar
• Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006;24:4441-7
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Johnson TR, Geyer CEJ, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2000;18:3151-63
   PubMed Web of Science ®Google Scholar
• Soepenberg O, de Jonge MJ, Sparreboom A, et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 2005;11(2 Pt 1):703-11
   PubMed Web of Science ®Google Scholar
• Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives. WO9835940; 1998
   Google Scholar
• Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives. WO9807727; 1998
   Google Scholar
• Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives. US5910491; 1999
   Google Scholar
• Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992;84(12):972-4
   PubMed Web of Science ®Google Scholar
• Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54(14):3723-5
   PubMed Web of Science ®Google Scholar
• Pollack IF, Erff M, Bom D, et al. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 1999;59(19):4898-905
   PubMed Web of Science ®Google Scholar
• Van Hattum AH, Schluper HM, Hausheer FH, et al. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int J Cancer 2002;100(1):22-9
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh. Camptothecin analogs and methods of preparation thereof. WO9909996; 1999
   Google Scholar
• University of Pittsburgh. Camptothecin analogs and methods of preparation thereof. WO0035924; 2000
   Google Scholar
• University of Pittsburgh. Camptothecin analogs and methods of preparation thereof. US6136978; 2000
   Google Scholar
• University of Pittsburgh. Camptothecin analogs and methods of preparation thereof. US6150343; 2000
   Google Scholar
• Societé de conseils de recherché et d'applications scientifiques. Novel counterparts of camptothecin, their application as medicine and pharmaceutical compositions containing them. WO9828305; 1998
   Google Scholar
• Societé de conseils de recherché et d'applications scientifiques. Camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing said analogs. US5981542; 1999
   Google Scholar
• Societé de conseils de recherché et d'applications scientifiques. Camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing said analogs. US6339091; 2002
   Google Scholar
• Lesueur-Ginot L, Demarquay D, Kiss R, et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 1999;59(12):2939-43
   PubMed Web of Science ®Google Scholar
• Lavergne O, Lesueur-Ginot L, Pla Rodas F, et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 1998;41(27):5410-9
   PubMed Web of Science ®Google Scholar
• Larsen AK, Gilbert C, Chyzak G, et al. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 2001;61(7):2961-7
   PubMed Web of Science ®Google Scholar
• Troconiz IF, Garrido MJ, Segura C, et al. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 2006;57(6):727-35
   PubMed Web of Science ®Google Scholar
• Scott L, Soepenberg O, Verweij J, et al. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol 2007;18(3):569-75
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh. Synthesis of silyl camptothecins and silyl homocamptothecins. US6372906; 2002
   Google Scholar
• Bionumerik Pharmaceuticals, Inc; Hausheer Frederick Camptothecin-analog with a novel, “flipped” lactone-stable. E-ring and methods for making and using same. WO07123995; 2007
   Google Scholar
• Research Triangle Institute. Camptothecin analogs having an E-ring ketone. US0266804; 2004
   Google Scholar
• Chugai Pharmaceutical Co. Ltd; Fukuda Hiroshi. Novel process for the preparation of hexacyclic compounds. WO04073601; 2004
   Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite; Istituto nazionale per lo studio e la cura dei tumori. Camptothecin derivatives having antitumor activity. EP1044977; 2000
   Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite; Istituto nazionale per lo studio e la cura dei tumori. Camptothecin derivatives having antitumor activity. WO0053607; 2000
   Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite; Istituto nazionale per lo studio e la cura dei tumori. 7-imino derivatives of camptothecin having antitumor activity. WO04083214; 2004
   Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite; Istituto nazionale per lo studio e la cura dei tumori. Camptothecin derivatives having antitumor activity. US0018988; 2004
   Google Scholar
• Istituto nazionale per lo studio e la cura dei tumori. Camptothecin derivatives and the use thereof as antitumor agents. WO9731003; 1997
   Google Scholar
• Sawada S, Nokata K, Furuta T, et al. Chemical modification of an antitumor alkaloid camptothecin: synthesis and antitumor activity of 7-C-substituted camptothecins. Chem Pharm Bull (Tokyo) 1991;39(10):2574-80
   PubMed Web of Science ®Google Scholar
• Supko JGAL, Wen P, Cassidy K, et al. Pharmacokinetics of gimatecan, an orally administered camptothecin analogue, in patients with malignant gliomas. J Clin Oncol ASCO Ann Meeting Proc 2004;22:2039
   Google Scholar
• Zhu AXRN, Clark JW, Safran H, et al. Phase I trial of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors [abstract 557]. Proc Am Soc Clin Oncol 2003;22:557
   Google Scholar
• Sessa C, Cresta S, Cerny T, et al. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol 2007;18(3):561-8
   Google Scholar
• De Cesare M, Pratesi G, Perego P, et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 2001;61(19):7189-95
   PubMed Web of Science ®Google Scholar
• Dallavalle S, Ferrari A, Biasotti B, et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 2001;44(20):3264-74
   PubMed Web of Science ®Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite; Istituto nazionale per lo studio e la cura dei tumori. 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups. WO05005431; 2005
   Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite. Stereoselective process and crystalline forms of a camptothecin. WO06067092; 2006
   Google Scholar
• SIGMA-TAU Industrie Farmaceutiche Riunite. Treatment of drug-resistant tumors. WO07071603; 2007
   Google Scholar
• Dr. Reddy's Research Foundation. Novel water-soluble C-ring analogues of 20(S)-camptothecin. WO9746563; 1997
   Google Scholar
• Dr. Reddy's Laboratories Limited. A process for the preparation of 10-hydroxy-9-N,N-dimethylaminomethyl-5-(2´-fluoroethoxy)-20(S)-camptothecin hydrochloride. WO03068778; 2003
   Google Scholar
• Dr. Reddy's Research Foundation. Water soluble analogs of 20(S)-camptothecin. US6214836; 2001
   Google Scholar
• Dr. Reddy's Research Foundation. Water soluble analogs of 20(S)-camptothecin. US6177439; 2001
   Google Scholar
• Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories, Inc. Crystalline form of 5(S)- (2´-hydroxyethoxy)-20(S)-camptothecin WO07140239; 2007
   Google Scholar
• Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories, Inc. 5(S)- (2´-hydroxyethoxy)-20(S)-camptothecin and its preparation and use for the treatment of cancer. WO07140248; 2007
   Google Scholar
• Chatterjee A, Digumarti R, Katneni K, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol 2005;45(4):453-60
   PubMed Web of Science ®Google Scholar
• Indena S.p.A. Camptothecin analogues, process for their preparation, use and formulations containing them. WO07006543; 2007
   Google Scholar
• Indena S.p.A. Camptothecin derivatives with antitumor activity. WO08012003; 2008
   Google Scholar
• Indena S.p.A. Camptothecin derivatives with antitumor activity. WO08011992; 2008
   Google Scholar
• Indena S.p.A. Camptothecin derivatives with antitumor activity. WO08011994; 2008
   Google Scholar
• Samori C, Guerrini A, Varchi G, et al. Thiocamptothecin. J Med Chem 2008;51(10):3040-4
   PubMed Web of Science ®Google Scholar
• Hautefaye P, Cimetiere B, Pierre A, et al. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorg Med Chem Lett 2003;13(16):2731-5
   PubMed Web of Science ®Google Scholar
• Lansiaux A, Leonce S, Kraus-Berthier L, et al. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Mol Pharmacol 2007;72(2):311-9
   PubMed Web of Science ®Google Scholar
• Adire et compagnie. Nouveaux composés analogues de la camptothécine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. EP1101765; 2001
   Google Scholar
• Takagi K, Dexheimer TS, Redon C, et al. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther 2007;6(12 Pt 1):3229-38
   Google Scholar